Community-Acquired Pneumonia Spoon-Feed

Happy Thanksgiving!
On this day of literal spoon-feeding…we want to pause and say thanks. You read, you subscribe, you spontaneously share (looking at you reddit!) – THANK YOU for supporting JournalFeed. Also, my thanks to the growing JF team. We couldn’t touch as many lives without you!
Clay
Clay Smith
Chief Metaphorical Spoon-Feeder

---

Written by Shannon Markus

Spoon Feed
This JAMA article reviews current evidence on pathogenesis, epidemiology, diagnosis, and treatment of community-acquired pneumonia.

Breathe easy – the essentials of tackling community-acquired pneumonia
Pneumonia remains the most common infectious cause of hospitalization and death among U.S. adults, often leading to severe complications like sepsis and ARDS. Here is what you need to know.

• Epidemiology and Diagnosis: Older age is the strongest risk factor for CAP, although others include smoking and underlying lung disease. Diagnosis relies on clinical signs (e.g. fever, dyspnea) and radiographic findings. CXR is a common tool, though CT may reveal additional findings. Identifying the culprit pathogen is often difficult, and influenza and SARS-CoV-2 testing are crucial for guiding management. Reserve broader viral testing and blood cultures for patients with severe CAP or immunocompromising conditions.
• Disposition and Treatment: The Pneumonia Severity Index (PSI) aids hospitalization decisions, with Categories IV-V typically requiring inpatient care. 
• Outpatient Treatment: Patients without comorbidities may receive high-dose amoxicillin or doxycycline monotherapy. Those with comorbidities need combination therapy with β-lactam+macrolide, such as amoxicillin/clavulanate with azithromycin.
• Hospitalized CAP: For non-severe cases, empirical treatment includes a β-lactam (e.g. ceftriaxone) + macrolide (e.g. azithromycin). Use respiratory fluoroquinolones only if severely penicillin-allergic, as they carry risks like C. difficile infection, tendon rupture, and resistance. Severe (ICU) cases require similar regimens, emphasizing β-lactam/macrolide combinations.
• Special Considerations: 
  • Avoid empirical anti-anaerobic agents like clindamycin/metronidazole to reduce both C. difficile colitis and mortality risk.
  • Reserve MRSA and pseudomonal coverage for patients with those specific risk factors.
  • If confirmed viral CAP, antibiotics should likely be withheld due to low rates of bacterial co-infection.
  • Steroids have potential benefit only in COVID-19 CAP with hypoxia and severe non-COVID-19 CAP.
  • De-escalate therapy based on clinical response and microbiological results, with 3-5 days of therapy often being sufficient. For secondary prevention, advise alcohol and smoking cessation, vaccination, and oral hygiene.

How will this affect my practice?
This was a great review on the latest recommendations for evaluating and managing patients with community-acquired pneumonia. It emphasizes the importance of balancing clinical judgment with decision tools like PSI and provides clear guidance on empiric antibiotic choices for different patient groups. It makes me feel better about my current practice of deferring antibiotics in confirmed viral CAP (unless otherwise indicated) and pulling the trigger on CT when I have a high suspicion for pneumonia but lack supporting radiographic evidence.

Source
Community-Acquired Pneumonia: A Review. JAMA. 2024 Oct 15;332(15):1282-1295. doi: 10.1001/jama.2024.14796. PMID: 39283629